A Phase 3, Randomized, Double-Blind, 52-week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants with Nonsegmental Vitiligo
A Phase 3, Randomized, Double-Blind, 52-week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants with Nonsegmental Vitiligo
At Pivotal Research we are dedicated to improving patient care and advancing medical knowledge through cutting-edge clinical trials and research.
We use cookies to enhance your experience on our website, analyze site traffic, and personalize content and ads. By continuing to browse the site, you consent to our use of cookies in accordance with our Cookie Policy.